QC
TSVT

Quantedge Capital’s 2seventy bio TSVT Stock Holding History

Quantedge Capital’s Portfolio TSVT Stock Details TSVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-14,900
Closed -$197K – 270
2022
Q2 		$197K Sell
14,900
-20,900
-58% -$285K 0.04% 240
2022
Q1 		$611K Buy
+35,800
New +$607K 0.18% 123

Other funds holding TSVT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Quantedge Capital's TSVT Position: Q3 2022 in Review

Quantedge Capital sold out of 2seventy bio (TSVT) in Q3 2022, closing a stake of 14,900 shares — an estimated $197K sold.

Quantedge Capital first reported a position in TSVT in Q1 2022 and held it in 2 quarters. The position peaked at $611K in Q1 2022. 133 funds tracked by Wall St. Rank hold TSVT as of Q3 2022.

  • Quantedge Capital reported no remaining 2seventy bio position as of Q3 2022 after selling out during the quarter.
  • Quantedge Capital sold 14,900 2seventy bio shares in Q3 2022, an estimated $197K.
  • Quantedge Capital first reported a position in 2seventy bio in Q1 2022 and held it in 2 quarters.
  • Quantedge Capital's 2seventy bio position peaked at $611K in Q1 2022.
  • 133 funds tracked by Wall St. Rank held 2seventy bio as of Q3 2022.

Based on Quantedge Capital's 13F filing for Q3 2022, filed 10 Nov 2022.